#USA #Oakland #Integrated Benefits Institute #Employee Benefits #High-Cost Therapies

The Challenges of Integrating High-Cost Therapies into Employee Benefits

The recent report released by the Integrated Benefits Institute (IBI) sheds light on the evolving landscape of employee benefits, particularly focusing on the challenges employers face when integrating high-cost therapies. High-cost therapies include advanced treatments like cell and gene therapies (CGTs) and medications targeting specific health conditions, such as GLP-1 medications used for diabetes and obesity.

Current Adoption Rates

As of the report's release, approximately 33% of employers currently include CGTs in their benefits packages. Furthermore, 36% of companies are actively assessing strategies to adopt these innovative therapies. Interestingly, it's noted that 58% of those not currently offering CGTs plan to introduce these benefits within the next two years. This demonstrates a significant shift in perspective towards CGTs, as 90% of employers relate the potential benefits of CGTs to increased employee productivity, while 91% recognize their lifesaving capabilities that could prevent more extensive and expensive treatments down the line.

Factors Influencing Adoption

A key finding indicates that the existence of stop-loss (SL) insurance coverage plays a crucial role in predicting whether an organization adopts CGT benefits. Businesses with higher revenue and who have SL coverage report a 72% adoption rate for CGTs. In contrast, small organizations that lack SL coverage only achieve a 28% adoption rate. Dr. Sera-Leigh Ghouralal, a Senior Researcher at IBI, emphasizes the connection between an organization's readiness, including robust stop-loss coverage and ethical frameworks, and the readiness to implement CGT benefits. These firms that are aware of CGT potential are more likely to act, with the adoption likelihood being over twice as high.

Knowledge Gaps and Consultant Insights

The findings also reveal a disparity among consultants, with about 80% expressing the need for improved information regarding CGT benefits. This gap leads to hesitation among their clients, as 59% of consultants report that their clients are reluctant to adopt these advanced treatment options. Additionally, 69% identified the ability to amortize costs as a significant factor in the adoption process, reflecting the financial considerations organizations must contend with.

GLP-1 Medications Coverage

When it comes to GLP-1 medications, 87% of organizations provide some level of coverage. The report details that 35% cover diabetes treatments exclusively, while 23% include care for obesity and cardiovascular risk reduction, and 29% offer comprehensive coverage for all indications. Nonetheless, 11.7% of the participating organizations do not currently provide any coverage for GLP-1 therapies. Interestingly, 43% of these non-adopters plan to introduce such coverage in the next 12 to 24 months, while 47% have no immediate intention to implement it.

Long-Term Benefits vs. Initial Costs

Although the initial costs associated with CGTs and GLP-1 medications might seem substantial, the long-term benefits—including reduced disability claims and improved employee productivity—make these investments potentially lucrative. Organizations looking to stay competitive in employee benefits can significantly benefit by addressing knowledge limitations, fostering a supportive workplace culture, and carefully deliberating the financial implications of these therapies.

The importance of informed decision-making and strategic planning in employee benefits is paramount, with the recent IBI report serving as a guiding resource for organizations navigating these complex challenges. To gain deeper insights into these findings and engage with further data, organizations are encouraged to reach out to the IBI directly.

For more comprehensive information, please contact Colby Gray at email protected] or visit [www.ibiweb.org.

About Integrated Benefits Institute

The Integrated Benefits Institute is a significant player in health-related research, serving over 1,600 employer and supplier members across the country. Their tools and research are vital in helping businesses connect health programs to improved productivity outcomes and overall enhanced business performance.